A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Civacir® 10%, Hepatitis C Immune Globulin Intravenous (Human) is a high-titer human
polyclonal immune globulin (IgG) containing a diversity of antibodies that target and bind
the hepatitis C virus (HCV) to prevent infection. Subjects who reduce their viral load to
less than 100 IU/ml HCV RNA through up to 16 weeks of antiviral therapy prior to liver
transplant are enrolled in the study. There is no requirement to reach undetectable virus
prior to transplant as the function of Civacir® is to neutralize any remaining virus in
circulation.
Subjects randomized to Civacir® treatment arms receive study drug infusions starting on the
day of liver transplant followed by 15 doses over a 10 week period to prevent the recurrence
of quantifiable Hepatitis C Virus (HCV) after liver transplant. The study will evaluate
dosing arms ranging from 200 mg/kg to 400 mg/kg compared to a control arm. For the primary
endpoint, efficacy is defined as persistent viral load suppression maintaining HCV RNA
levels below the lower limit of quantitation as determined by central laboratory Polymerase
Chain Reaction (PCR) at 12 weeks post-liver transplant and then at 24 weeks post-liver
transplant to demonstrate durability of effect.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Determine the efficacy of Civacir® in preventing post-transplant HCV recurrence at 12 weeks post transplant
The primary objective is to assess the effect of administering Civacir® anti-HCV immunoglobulin therapy on prevention of orthotopic liver transplant (OLT) HCV recurrence, as measured by the proportion of subjects with unquantifiable HCV RNA levels at 12 weeks post-OLT, compared to the control group (not treated with Civacir® and considered standard of care).
12 weeks
No
Norah Terrault, MD, MPH
Principal Investigator
University of California, San Francisco
United States: Food and Drug Administration
988
NCT01804829
May 2013
December 2014
Name | Location |
---|